New cocktail of cancer drugs tested for Tough-to-Treat myeloma

NCT ID NCT01297764

Ongoing Disease control Sponsor: Hackensack Meridian Health Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of four drugs—carfilzomib, lenalidomide, vorinostat, and dexamethasone—in people with multiple myeloma that has relapsed or not responded to prior treatment. The goal is to find a safe dose and see if the combination helps control the cancer. Seventeen participants are enrolled in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carfilzomib, lenalidomide, vorinostat, and dexamethasone
What this could lead to: If it works, this could offer a new treatment option for people with multiple myeloma that has come back or stopped responding to other therapies.
What could go wrong: This is an early-phase trial with only 17 participants, so results may not apply to everyone. The drug combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.